Revenue

6 Months Ended

Jun. 30, 2024

Revenue

Revenue

3.  Revenue

In connection with our acquisition of 51% ownership of PET Labs Pharmaceuticals in October 2023, we manufacture and sell nuclear medical doses for PET scanning in South Africa. For the three and six months ended June 30, 2024, the Company recognized revenue of $1,022,299 and $1,862,653, respectively. Since the acquisition did not occur until October 2023, there is no accounts receivable as of January 1, 2023 and no revenue was recognized for the three or six months ended June 30, 2023.

The following table presents changes in the Company’s accounts receivable for the six months ended June 30, 2024:

	Balance as of December 31, 2023		Additions		Deductions			Balance as of June 30, 2024
Accounts receivable	$	216,504	$	1,862,653	$	(1,563,707	)	$	515,450